journal
MENU ▼
Read by QxMD icon Read
search

Cancer Treatment Reviews

journal
https://read.qxmd.com/read/30708267/the-optimal-duration-of-adjuvant-endocrine-therapy-in-early-luminal-breast-cancer-a-concise-review
#1
REVIEW
Lorenzo Rossi, Amelia McCartney, Irene De Santo, Emanuela Risi, Erica Moretti, Luca Malorni, Laura Biganzoli, Angelo Di Leo
Patients with luminal early breast cancer are at risk of relapse, even after five years of adjuvant endocrine therapy. To date, no biomarkers have been clinically validated to identify those patients at risk of late recurrence, who might benefit from extended adjuvant endocrine therapy. In recent decades, multiple clinical trials have tested the role of extending adjuvant endocrine therapies in patients with luminal disease. However, the data currently at our disposal are conflicting. This article reviews all the major trials concerning extended adjuvant endocrine regimens, and formulates some general conclusions and hypotheses of future study...
January 25, 2019: Cancer Treatment Reviews
https://read.qxmd.com/read/30685576/drug-drug-interactions-in-breast-cancer-patients-treated-with-cdk4-6-inhibitors
#2
REVIEW
Stefano Fogli, Marzia Del Re, Giuseppe Curigliano, Ron H van Schaik, Patrizio Lancellotti, Romano Danesi
CDK4/6 inhibitors are a new class of anticancer drugs used for the treatment of women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. Polypharmacy is a well-known problem in advanced cancer causing potential drug-drug interactions (DDIs), which, in turn, may limit the therapeutic value of CDK4/6 inhibitors. Therefore, understanding the mechanisms underlying potential DDIs in patients taking CDK4/6 inhibitors may be useful in decision-making processes and represent an important step towards treatment personalization...
January 19, 2019: Cancer Treatment Reviews
https://read.qxmd.com/read/30658289/ehealth-for-improving-quality-of-life-in-breast-cancer-patients-a-systematic-review
#3
REVIEW
Stefano Triberti, Lucrezia Savioni, Valeria Sebri, Gabriella Pravettoni
Breast cancer patients (and survivors) use to deal with important challenges daily, such as coping with stress and depression, and adopting healthy lifestyles in order to improve treatment effectiveness; moreover, some experiential issues are quite specific of this disease, such as sexuality and fertility disfunctions after hormonal therapy, and distortions in body image after breast surgery. Recent literature highlighted the utility of eHealth or the use of new technologies to promote health management and quality of life in chronic diseases generally...
January 10, 2019: Cancer Treatment Reviews
https://read.qxmd.com/read/30738364/therapeutic-options-for-first-line-metastatic-castration-resistant-prostate-cancer-suggestions-for-clinical-practise-in-the-chaarted-and-latitude-era
#4
REVIEW
Marcello Tucci, Orazio Caffo, Consuelo Buttigliero, Carla Cavaliere, Carmine D'aniello, Massimo Di Maio, Stefania Kinspergher, Francesca Maines, Mimma Rizzo, Sabrina Rossetti, Antonello Veccia, Giorgio Vittorio Scagliotti, Gaetano Facchini
In few years the scenario of metastatic prostate carcinoma treatment has radically changed due to improved knowledge of those mechanisms responsible of prostatic cancer cells survival and proliferation. Five new therapeutic agents (abiraterone acetate, enzalutamide, cabazitaxel, radium-223, sipuleucel-T), all able to improve overall survival, have been introduced in the management of metastatic castration-resistant prostate cancer. Moreover, recent evidences showed that adding docetaxel chemotherapy or abiraterone acetate to androgen deprivation therapy significantly increases overall survival of de novo castration-sensitive metastatic prostate cancer patients...
January 7, 2019: Cancer Treatment Reviews
https://read.qxmd.com/read/30665053/innovation-in-oncology-clinical-trial-design
#5
REVIEW
J Verweij, H R Hendriks, H Zwierzina
Progress in and better understanding of cancer biology causes a shift in cancer drug development: away from the evaluation of drugs in large tumour histology defined patient populations towards targeted agents in increasingly heterogeneous molecularly defined subpopulations. This requires novel approaches in clinical trial design by academia and industry, and development of new assessment tools by regulatory authorities. Pharmaceutical industry is developing new targeted agents generating many clinical studies, including target combinations...
January 4, 2019: Cancer Treatment Reviews
https://read.qxmd.com/read/30639801/systematic-review-and-meta-analysis-of-patient-reported-outcomes-for-nurse-led-models-of-survivorship-care-for-adult-cancer-patients
#6
REVIEW
Leanne Monterosso, Violet Platt, Max Bulsara, Melissa Berg
PURPOSE: This systematic review aimed to determine the effectiveness of nurse-led cancer survivorship care, compared with existing models of care, on patient reported outcomes for cancer survivors. METHODS: Randomised and non-randomised controlled trials and controlled before-after studies published in English between 1 January 2007 and 28 July 2017 were identified in bibliographic databases including Medline, Pubmed and PsychINFO. Included studies described nurse-led cancer care after treatment to adults (age ≥18 years) <2 years post treatment completion...
January 3, 2019: Cancer Treatment Reviews
https://read.qxmd.com/read/30616224/retreatment-with-anti-egfr-monoclonal-antibodies-in-metastatic-colorectal-cancer-systematic-review-of-different-strategies
#7
REVIEW
Gianluca Mauri, Elio Gregory Pizzutilo, Alessio Amatu, Katia Bencardino, Laura Palmeri, Erica Francesca Bonazzina, Federica Tosi, Giulia Carlo Stella, Giovanni Burrafato, Francesco Scaglione, Silvia Marsoni, Giulia Siravegna, Alberto Bardelli, Salvatore Siena, Andrea Sartore-Bianchi
BACKGROUND: Despite advances in precision oncology and immunotherapy of tumors, little progress has been made in metastatic colorectal cancer (mCRC) in recent years. Therefore, making the most of available therapies is a necessity. Several studies, based on the pulsatile behavior of RAS clones under EGFR blockade, investigated whether readministration of EGFR-targeted agents is effective beyond second line. METHODS: A systematic review of studies of retreatment with anti-EGFR monoclonal antibodies has been performed from January 2005 to December 2018 according to PRISMA criteria from PubMed, ESMO and ASCO meetings libraries and Clinicaltrial...
December 27, 2018: Cancer Treatment Reviews
https://read.qxmd.com/read/30572165/new-clinical-trial-designs-in-the-era-of-precision-medicine-an-overview-of-definitions-strengths-weaknesses-and-current-use-in-oncology
#8
REVIEW
Perrine Janiaud, Stylianos Serghiou, John P A Ioannidis
With expanding knowledge in tumor biology and biomarkers, oncology therapies are increasingly moving away from the "one-size-fits-all" rationale onto biomarker-driven therapies tailored according to patient-specific characteristics, most commonly the tumor's molecular profile. The advent of precision medicine in oncology has been accompanied by the introduction of novel clinical trial designs that aim to identify biomarker-matched subgroups of patients that will benefit the most from targeted therapies...
December 11, 2018: Cancer Treatment Reviews
https://read.qxmd.com/read/30543930/parp-inhibitors-in-ovarian-cancer
#9
REVIEW
Elisena Franzese, Sara Centonze, Anna Diana, Francesca Carlino, Luigi Pio Guerrera, Marilena Di Napoli, Ferdinando De Vita, Sandro Pignata, Fortunato Ciardiello, Michele Orditura
Poly-ADP-ribosepolymerase inhibitors (PARPis) are the most active and interesting therapies approved for the treatment of epithelial ovarian cancer. They have changed the clinical management of a disease characterized, in almost half of cases, by extreme genetic complexity and alteration of DNA damage repair pathways, particularly homologous recombination (HR) deficiency. In this review, we provide an updated overview of the available results of recent clinical trials on the three Food and Drug Administrationand European Medicines Agency approved PARPis in ovarian cancer: olaparib, niraparib, and rucaparib...
December 4, 2018: Cancer Treatment Reviews
https://read.qxmd.com/read/30551036/b-cell-and-b-cell-related-pathways-for-novel-cancer-treatments
#10
REVIEW
Ryuma Tokunaga, Madiha Naseem, Jae Ho Lo, Francesca Battaglin, Shivani Soni, Alberto Puccini, Martin D Berger, Wu Zhang, Hideo Baba, Heinz-Josef Lenz
B cells are recognized as the main effector cells of humoral immunity which suppress tumor progression by secreting immunoglobulins, promoting T cell response, and killing cancer cells directly. Given these properties, their anti-tumor immune response in the tumor micro-environment (TME) is of great interest. Although T cell-related immune responses have become a therapeutic target with the introduction of immune checkpoint inhibitors, not all patients benefit from these treatments. B cell and B cell-related pathways (CCL19, -21/CCR7 axis and CXCL13/CXCR5 axis) play key roles in activating immune response through humoral immunity and local immune activation via tertiary lymphoid structure (TLS) formation...
December 3, 2018: Cancer Treatment Reviews
https://read.qxmd.com/read/30685613/vulvar-malignant-melanoma-pathogenesis-clinical-behaviour-and-management-review-of-the-literature
#11
REVIEW
Florine L Boer, Mieke L G Ten Eikelder, Ellen H Kapiteijn, Carien L Creutzberg, Khadra Galaal, Mariette I E van Poelgeest
Vulvar malignant melanoma (VMM) is a rare disease, accounting for 5% of all vulvar malignancies and is characterized by low survival and high recurrence rates. It is considered as a distinct entity of mucosal melanoma. Prognostic factors are higher age, advanced Breslow thickness, and lymph node involvement whilst central localization and ulceration status are still under debate. Surgery is the cornerstone for the treatment of primary VMM, however, it can be mutilating due to the anatomical location of the disease...
February 2019: Cancer Treatment Reviews
https://read.qxmd.com/read/30684842/oligometastatic-prostate-cancer-the-game-is-afoot
#12
REVIEW
Andrea Lancia, Thomas Zilli, Verane Achard, Piet Dirix, Wouter Everaerts, Alfonso Gomez-Iturriaga, Gianluca Ingrosso, Nick Liefhooghe, Raymond Miralbell, Shankar Siva, Kim Van der Eecken, Piet Ost
Oligometastatic prostate cancer represents an intermediate state between a localized tumor and widespread metastatic disease. Its specific clinical features suggest the existence of a distinct biology which still needs to be elucidated. New imaging techniques like prostate specific membrane antigen (PSMA) PET scans have shown to perform well in the staging and restaging of this category of patients, at different phases of disease evolution. Despite limited prospective evidence, metastasis-directed therapies (MDT) are emerging as valid treatment options able to postpone systemic therapies and probably improve survival outcome...
February 2019: Cancer Treatment Reviews
https://read.qxmd.com/read/30682661/circulating-tumor-dna-analysis-in-breast-cancer-is-it-ready-for-prime-time
#13
REVIEW
Giuseppe Buono, Lorenzo Gerratana, Michela Bulfoni, Nicoletta Provinciali, Debora Basile, Mario Giuliano, Carla Corvaja, Grazia Arpino, Lucia Del Mastro, Sabino De Placido, Michele De Laurentiis, Massimo Cristofanilli, Fabio Puglisi
Precision Medicine is becoming the new paradigm in healthcare as it enables better resources allocation, treatment optimization with a potential side-effects reduction and consequent impact on quality of life and survival. This revolution is being catalyzed by liquid biopsy technologies, which provide prognostic and predictive information for advanced cancer patients, without the analytical and procedural drawbacks of tissue-biopsy. In particular, circulating tumor DNA (ctDNA) is gaining momentum as a clinically feasible option capable to capture both spatial and temporal tumor heterogeneity...
February 2019: Cancer Treatment Reviews
https://read.qxmd.com/read/30623865/management-of-advanced-prostate-cancer-a-systematic-review-of-existing-guidelines-and-recommendations
#14
Athanasios Dellis, Flora Zagouri, Michalis Liontos, Dionysios Mitropoulos, Aristotelis Bamias, Athanasios G Papatsoris
The therapeutic landscape of advanced prostate cancer is continuously changing under the light of new available treatment options and the improved understanding of the molecular characteristics of the disease. The lack of high quality evidence regarding the sequencing of these treatments along with the earlier implementation of these therapeutic approaches during the course of the disease have created issues of dispute regarding the optimal treatment of patients with advanced prostate cancer. Therefore, we conducted a systematic review of the existing guidelines and recent randomized trials not included in these guidelines, and present a comprehensive analysis of the available treatment options in each of the stages of advanced prostate cancer, as well as the supportive treatments available for these patients...
February 2019: Cancer Treatment Reviews
https://read.qxmd.com/read/30597479/integrative-molecular-analysis-of-colorectal-cancer-and-gastric-cancer-what-have-we-learnt
#15
REVIEW
Avani Athauda, Eva Segelov, Zohra Ali, Ian Chau
Gastrointestinal (GI) malignancies comprise a diverse group of cancers with varying aetiology, clinical course, management and prognosis. Advances over the last decade in molecular diagnostics in colorectal cancer (CRC) have helped to improve our understanding of the underlying complex mechanisms in the development and progression of this highly heterogenous disease. Large scale integrative analysis has identified molecularly distinct subgroups of CRC with differing clinical behaviour. It was hoped that these discoveries would fuel the development of novel drug targets and new treatments to shift the management of advanced CRC from an empirical strategy to a biomarker driven approach based on underlying molecular characteristics...
February 2019: Cancer Treatment Reviews
https://read.qxmd.com/read/30530271/ovarian-protection-with-gonadotropin-releasing-hormone-agonists-during-chemotherapy-in-cancer-patients-from-biological-evidence-to-clinical-application
#16
REVIEW
Matteo Lambertini, Florence Horicks, Lucia Del Mastro, Ann H Partridge, Isabelle Demeestere
Survivorship issues are an area of crucial importance to be addressed as early as possible by all health care providers dealing with cancer patients. In women diagnosed during their reproductive years, the possible occurrence of chemotherapy-induced premature ovarian insufficiency (POI) is of particular concern being associated with important menopause-related symptoms, psychosocial issues as well as infertility. Temporary ovarian suppression by administering a gonadotropin-releasing hormone agonist (GnRHa) during chemotherapy has been studied to reduce the gonadotoxic impact of chemotherapy thus diminishing the chance of developing POI...
January 2019: Cancer Treatment Reviews
https://read.qxmd.com/read/30530009/proton-therapy-for-treatment-of-intracranial-benign-tumors-in-adults-a-systematic-review
#17
REVIEW
Paul Lesueur, Valentin Calugaru, Catherine Nauraye, Dinu Stefan, Kim Cao, Evelyne Emery, Yves Reznik, Jean Louis Habrand, Thomas Tessonnier, Abdulhamid Chaikh, Jacques Balosso, Juliette Thariat
INTRODUCTION: The depth-dose distribution of a proton beam, materialized by the Bragg peak makes it an attractive radiation modality as it reduces exposure of healthy tissues to radiations, compared with photon therapy Prominent indications, based on a long-standing experience are: intraocular melanomas, low-grade skull-base and spinal canal malignancies. However, many others potential indications are under investigations such as the benign morbid conditions that are compatible with an extended life-expectancy: low grade meningiomas, paragangliomas, pituitary adenomas, neurinomas craniopharyngioma or recurrent pleomorphic adenomas...
January 2019: Cancer Treatment Reviews
https://read.qxmd.com/read/30476750/targeting-the-pi3k-akt-mtor-pathway-in-biliary-tract-cancers-a-review-of-current-evidences-and-future-perspectives
#18
REVIEW
Francesca Corti, Federico Nichetti, Alessandra Raimondi, Monica Niger, Natalie Prinzi, Martina Torchio, Elena Tamborini, Federica Perrone, Giancarlo Pruneri, Maria Di Bartolomeo, Filippo de Braud, Sara Pusceddu
Biliary tract cancers (BTCs) are a group of invasive neoplasms, with increasing incidence and dismal prognosis. In advanced disease, the standard of care is represented by first-line chemotherapy with cisplatin and gemcitabine. In subsequent lines, no clear recommendations are currently available, highlighting the need for novel therapeutic approaches. The PI3K/AKT/mTOR pathway is a core regulator of cell metabolism, growth and survival, and is involved in BTCs carcinogenesis and progression. Mutations, gene copy number alterations and aberrant protein phosphorylation of PI3K, AKT, mTOR and PTEN have been thoroughly described in BTCs and correlate with poor survival outcomes...
January 2019: Cancer Treatment Reviews
https://read.qxmd.com/read/30468937/a-comprehensive-review-of-the-current-evidence-for-trabectedin-in-advanced-myxoid-liposarcoma
#19
REVIEW
Tarek Assi, Joseph Kattan, Elie El Rassy, Charles Honore, Sarah Dumont, Olivier Mir, Axel Le Cesne
Myxoid liposarcoma (MLS) is a rare mesenchymal tumor that constitutes 10-20% of all liposarcomas. MLS is a translocation-related sarcoma (TRS) related to the chromosomal translocation t(12:16) (q13:p11), producing the FUS-CHOP oncoprotein that constitutes one of the main targets of trabectedin in MLS patients. It is known to be chemosensitive namely to trabectedin in contrast to other soft tissue sarcomas. The efficacy of this agent in MLS have been demonstrated in different settings including treatment-naïve and pre-treated patients with both locally advanced and metastatic disease...
January 2019: Cancer Treatment Reviews
https://read.qxmd.com/read/30447470/updated-use-of-tace-for-hepatocellular-carcinoma-treatment-how-and-when-to-use-it-based-on-clinical-evidence
#20
REVIEW
Jean-Luc Raoul, Alejandro Forner, Luigi Bolondi, Tan To Cheung, Roman Kloeckner, Thierry de Baere
Hepatocellular carcinoma (HCC) is the most common primary liver cancer, representing the sixth leading cause of cancer and the third leading cause of cancer-related mortality. Patient stratification and treatment allocation are based on tumor stage, liver function, and performance status. According to the Barcelona Clinic Liver Cancer (BCLC) staging system, transarterial chemoembolization (TACE) is the first-line treatment for patients with intermediate stage HCC, including those with large or multinodular HCC, well-preserved liver function, and no cancer-related symptoms or evidence of vascular invasion or extrahepatic spread...
January 2019: Cancer Treatment Reviews
journal
journal
25655
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"